This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Feuerstein's Biotech-Stock Mailbag: Panacos

This column originally posted on at 6:59 a.m. EDT. For more information about subscribing to RealMoney , please click here.

The Biotech Mailbag is open. Our first email comes from Joe B., who asks for my thoughts on Panacos Pharmaceuticals (PANC).

Joe's email has been sitting in the mailbag for a long while, but it's timely this week because Panacos announced that company researchers have figured out a way to identify the sub-population of HIV patients who respond favorably to its experimental drug beviramat.

Cue the angels' trumpets because this is the first bit of encouraging news from Panacos and its beleaguered, delayed and generally dismal beviramat development program in at least a year and half.

Excuse the snark, but I'm a recovering Panacostal -- I actually liked this stock when it was much, much higher and you could make the case for beviramat being a $300-million or so HIV drug without anyone laughing at you.

Today, Panacos shares could find a home on the sale rack at a 99-cent store. So you understand my bitterness.

But that's all in the past. Today, Panacos sports a miserly $11 million enterprise value, and if you believe Wednesday's announcement, beviramat might be back on track. A real HIV drug has to be worth more than $11 million, right?

Yes, sure, except...

You see, while Panacos was shuffling its feet these past two years, the HIV-treatment market was changing. A lot of really good HIV drugs are on the market today, with more on the way ahead of beviramat. There are so many really good HIV drugs out there now, in fact, that it will be hard to find a place for beviramat except as a last-ditch drug for treating the most ill HIV/AIDS patients.
1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ELN $0.00 0.00%
PANC $0.00 0.00%
MRK $54.84 -1.61%
PFE $32.71 -0.61%
AAPL $93.74 -1.15%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs